You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a Functional Assessment for Children and Youth who are Hospitalized

    SBC: CreCare, LLC            Topic: NICHD

    Development of a Functional Assessment for Children and Youth who are Hospitalized Project Abstract The objective of this project is to develop a marketable clinician reportedjudgement based functional assessmentusing contemporary measurement technology that transforms the assessment of children hospitalized in the USItem response theoryIRTand computer adaptive testCATprinciples will be used to di ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Neonatal Jaundice Treatment Accelerator by Circumferential Redirection of Unused Phototherapy Light onto the Infants Untreated Skin Surface

    SBC: Arbor Grace Inc.            Topic: NICHD

    PROJECT SUMMARY ABSTRACT Neonatal jaundice continues to be a significant global problem affectingof preterm andof term neonates while severe neonatal jaundice affects at leastneonates annuallyJaundice and jaundice related complications like Kernicterus Spectrum DisorderKDSare gaining recognition among the worldandapos s health policy leaders as an important area for further research and developmen ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Improving treatment options and outcomes in fungal keratitis

    SBC: TranZ Biosciences LLC            Topic: N

    ABSTRACT Fungal keratitisprimarily caused by CandidaFusariumor Aspergillus speciesis a leading cause of blindness among corneal diseasesAmphotericin BAmBremains the gold standard in the treatment of Candida keratitis and is also the fallback option for other corneal fungal infectionsAlthough widely used off label in ocular infectionsophthalmic AmB formulations are not available commerciallyThe com ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Process for GMP Production of Natural THC and CBD

    SBC: ElSohly Laboratories, Incorporated            Topic: R41

    Development Process for Production of Natural THC and CBD AbstractTetrahydrocannabinolTHCand cannabidiolCBDare two major constituents of the cannabis plant that have pharmacological properties with potential therapeutic value in several disease conditionsWhileTHC has already been in use clinically for two indicationsnausea and vomiting in cancer patients receiving chemotherapy and appetite stimula ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Low Cost Electrochemical Gas Phase Nitric Oxide Generator for Biomedical Applications

    SBC: NOTA Laboratories, Inc.            Topic: NHLBI

    ABSTRACTTherapeutic use of gas phase nitric oxideNOhas several important applications in medicineSince its first medical application more thanyears agoinhaled nitric oxideINOhas become a mainstay of intensive care for lung failure patientsAs a pulmonary vasodilatorINO is essential in neonatologylung transplantationand pulmonary hypertensionAs an inhaled antiseptic agentNO has been proposed in the ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Combination Therapy to Treat Biofilm-based Pneumonia Infections

    SBC: TSRL, INC.            Topic: NIAID

    Abstract Bronchiectasis is a lung pathology characterized by a permanent dilation of the bronchi and is associated with a chronic cough, sputum production and recurrent respiratory infections. Cystic fibrosis (CF) is one of the best understood inherited conditions that leads to progressive bronchiectasis, chronic bacterial infection and premature mortality. Both non-CF bronchiectasis (NCFB) and CF ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a lead cyclic-PDZ-Enhancer drug for Anxiety and Depression

    SBC: Aingeal, LLC            Topic: 101

    Major depressive disorder is a debilitating mood disorder that affects ~7% of US adults in their lifetime, costing the U.S. economy more than $200 billion a year. Drugs that increase monoaminergic signaling are the mainstay of depression therapy, but have a delayed onset of action and are only effective in about 50% of affected patients. Aberrant brain-derived neurotrophic factor (BDNF) signaling ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Personalized Bioreactor for Cell Culturing in Alginate Tubes

    SBC: CellGro Technologies, LLC            Topic: 400

    PROJECT SUMMARY ABSTRACT SignificanceCell therapy is expected to become an important method to treat chronic diseases such as diabetesrheumatoid arthritisretinal diseases like macular degeneration and certain types of cancersThe cell therapy market in general is projected to become a $billion industry byHuman pluripotent stem cellshPSCsare of particular importance since their utility as a source f ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Targeted Therapy for Myasthenia Gravis

    SBC: ARC Biotechnology LLC            Topic: NINDS

    Myasthenia gravis is a severe neuromuscular disease primarily caused by complement activating autoantibodies directed towards the skeletal muscle acetylcholine receptor. Present treatments are ineffectiveand uniformly have adverse effects, which negatively impact quality of life. Despite being a rare disease, myasthenia gravis is a costly one with a hospitalization expense of half a billion dollar ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Noregen(TM), a regenerative medicine ocular therapeutic

    SBC: Retinal Solutions LLC            Topic: NEI

    Project Summary Diabetic retinopathy and Retinal Vein OcclusionRVOaccount for most new cases of blindness in the United StatesThese diseases are marked by retinal swellingedemaand new leaky vessel formationneovascularizationtriggered by pathologically high concentrations of Vascular Endothelial Growth FactorVEGFThe primary treatment is VEGF blocking drugs to control the neovascularization and edem ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government